These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33972056)

  • 1. Shedding light on therapeutics in alopecia and their relevance to COVID-19.
    Fagan N; Meah N; York K; Bokhari L; Fletcher G; Chen G; Tobin DJ; Messenger A; Irvine AD; Sinclair R; Wall D
    Clin Dermatol; 2021; 39(1):76-83. PubMed ID: 33972056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familiar Dermatologic Drugs as Therapies for COVID-19.
    Ortega-Peña M; González-Cuevas R
    Actas Dermosifiliogr (Engl Ed); 2021 Feb; 112(2):118-126. PubMed ID: 33045209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS CoV-2 infection among patients using immunomodulatory therapies.
    Winthrop KL; Brunton AE; Beekmann S; Polgreen P; Baddley J; Saag KG; Calabrese C; Calabrese L; Robinson PC; Wallace ZS; Curtis JR;
    Ann Rheum Dis; 2021 Feb; 80(2):269-271. PubMed ID: 32759259
    [No Abstract]   [Full Text] [Related]  

  • 4. Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.
    Galimberti F; McBride J; Cronin M; Li Y; Fox J; Abrouk M; Herbst A; Kirsner RS
    Clin Dermatol; 2020; 38(6):775-780. PubMed ID: 32419721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine use and COVID-19 concerns among alopecia patients: A cross-sectional survey study.
    Pathoulas JT; Flanagan KE; Walker CJ; Pupo Wiss IM; Hagigeorges D; Senna MM
    Dermatol Ther; 2020 Nov; 33(6):e14529. PubMed ID: 33174299
    [No Abstract]   [Full Text] [Related]  

  • 8. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
    Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
    Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug treatments for covid-19: living systematic review and network meta-analysis.
    Siemieniuk RA; Bartoszko JJ; Zeraatkar D; Kum E; Qasim A; Martinez JPD; Izcovich A; Lamontagne F; Han MA; Agarwal A; Agoritsas T; Azab M; Bravo G; Chu DK; Couban R; Devji T; Escamilla Z; Foroutan F; Gao Y; Ge L; Ghadimi M; Heels-Ansdell D; Honarmand K; Hou L; Ibrahim Q; Khamis A; Lam B; Mansilla C; Loeb M; Miroshnychenko A; Marcucci M; McLeod SL; Motaghi S; Murthy S; Mustafa RA; Pardo-Hernandez H; Rada G; Rizwan Y; Saadat P; Switzer C; Thabane L; Tomlinson G; Vandvik PO; Vernooij RW; Viteri-García A; Wang Y; Yao L; Zhao Y; Guyatt GH; Brignardello-Petersen R
    BMJ; 2020 Jul; 370():m2980. PubMed ID: 32732190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network.
    Solé G; Salort-Campana E; Pereon Y; Stojkovic T; Wahbi K; Cintas P; Adams D; Laforet P; Tiffreau V; Desguerre I; Pisella LI; Molon A; Attarian S;
    Rev Neurol (Paris); 2020 Jun; 176(6):507-515. PubMed ID: 32354651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
    He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
    Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.
    Pereira BB
    J Toxicol Environ Health B Crit Rev; 2020 May; 23(4):177-181. PubMed ID: 32281481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Glucocorticoids in the Management of COVID-19.
    Alexaki VI; Henneicke H
    Horm Metab Res; 2021 Jan; 53(1):9-15. PubMed ID: 33207372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
    Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
    Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.